

NOVARTIS AG

ISIN: CH0012005267

WKN: 1200526

Overview

2024/04/23 16:54:16

Price

89.53 CHF

Difference ▲ 2.48% (2.17)

General attributes

ISIN CH0012005267

Symbol NOVN

Exchange SIX Swiss Exchange

Currency CHF

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 175,841 EUR

Benchmark SWISS MARKET INDEX

Market data

Bid (Bid size) 89.52 CHF (397)

Ask (Ask size) 89.54 CHF (1,005)

Open 90.08 CHF

High 92.06 CHF

Low 89.00 CHF

Close (prev. day) 87.36 CHF

VWAP 90.812746 CHF

Volume (pcs) 5,888,685

Trading volume 534,767,654.70

Number of trades 34,446

Last size 232


Futures and Options

Related Futures 30

Related Options -

PDF Downloads

Company report: NOVARTIS AG



Recent research

| on instrument | on sector | on market | |
|---------------|-----------|-----------------------|----------|
| Date | | Headline | Download |
| 2024/04/03 | | Global Equity Ratings | |
| 2024/03/13 | | Global Equity Ratings | |
| 2024/02/22 | | Global Equity Ratings | |
| 2024/02/14 | | Global Equity Ratings | |
| 2024/01/23 | | Global Equity Ratings | |

Details

2024/04/23 16:54:16

Price

89.53 CHF

Difference ▲ 2.48% (2.17)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | CH0012005267 |
| Symbol | NOVN |
| Exchange | SIX Swiss Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 175,841 EUR |
| Benchmark | SWISS MARKET INDEX |


Market data

| | |
|-------------------|-------------------|
| Bid (Bid size) | 89.52 CHF (397) |
| Ask (Ask size) | 89.54 CHF (1,005) |
| Open | 90.08 CHF |
| High | 92.06 CHF |
| Low | 89.00 CHF |
| Close (prev. day) | 87.36 CHF |
| VWAP | 90.812746 CHF |
| Volume (pcs) | 5,888,685 |
| Trading volume | 534,767,654.70 |
| Number of trades | 34,446 |
| Last size | 232 |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|--------|--------|--------|
| Perf (%) | +3.02% | -1.74% | +7.63% |
| Perf (abs.) | +2.56 | -1.55 | +6.19 |
| Beta | 0.81 | 0.92 | 0.79 |
| Volatility | 17.26 | 17.83 | 17.41 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 85.45 CHF (3,247,032) |
| Ø price 30 days Ø volume 30 days (pcs.) | 86.34 CHF (3,365,044) |
| Ø price 100 days Ø volume 100 days (pcs.) | 88.11 CHF (3,162,009) |
| Ø price 250 days Ø volume 250 days (pcs.) | 88.66 CHF (3,092,908) |
| YTD High date | 94.52 CHF (2024/01/22) |
| YTD Low date | 83.63 CHF (2024/04/19) |
| 52 Weeks High date | 94.77 CHF (2023/09/29) |
| 52 Weeks Low date | 83.00 CHF (2023/10/24) |

All listings for NOVARTIS AG

| Exchange 📍 | Date | Time | Price | Trading volume (mio.) | Number of trades |
|---|------------|-------|------------|-----------------------|------------------|
| Stuttgart | 2019/06/28 | 21:58 | 80.10 EUR | 0.04 | 11 |
| SIX Swiss Exchange | 2024/04/23 | 16:54 | 89.53 CHF | 534.77 | 34,446 |
| London Stock Exchange European Trade Reporting | 2024/04/23 | 15:35 | 89.205 CHF | 4.50 | 19 |
| Hanover | 2019/06/28 | 08:01 | 80.10 EUR | 0.00 | 2 |
| Hamburg | 2019/06/28 | 14:05 | 80.19 EUR | 0.08 | 4 |

| | | | | | | |
|------------------------|----------------|-------|-----------|------|--|----|
| | 06/28 | | | | | |
| Frankfurt | 2019/ 06/28 | 19:57 | 80.16 EUR | 0.13 | | 13 |
| FINRA other OTC Issues | 2024/ 04/23 | 16:12 | 96.00 USD | 0.37 | | 14 |
| Duesseldorf | 2019/ 06/28 | 14:08 | 80.18 EUR | 0.00 | | 2 |
| Berlin | 2019/ 06/28 | 18:45 | 80.40 EUR | 0.00 | | 16 |

Company profile

Company Logo



Contact Details

NOVARTIS AG

--

Lichtstrasse 35 - 4056 Basel

Telefon: +41-61-324-11-11

Fax: +

E-mail: -

PDF Downloads

Company report: NOVARTIS AG



Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Members of Management Board

| | |
|-------------------------|-------------------------------|
| Vasant (Vas) Narasimhan | Chairman of Managing Board |
| Klaus Moosmayer | Member of Executive Committee |
| Steffen Lang | Member of Executive Committee |
| Aharon Gal | Member of Executive Committee |
| Fiona H. Marshall | Member of Executive Committee |
| Harry Kirsch | Member of Executive Committee |
| Karen Hale | Member of Executive Committee |
| Kees Rokx | Member of Executive Committee |
| Lutz Hegemann | Member of Executive Committee |
| Michelle Weese | Member of Executive Committee |
| Patrick Horber | Member of Executive Committee |
| Rob Kowalski | Member of Executive Committee |
| Shreeram Aradhye | Member of Executive Committee |
| Victor Bulto | Member of Executive Committee |

Board of directors

| | |
|---------------------|--------------------------------------|
| Charles Sawyers | Member of the administrative board |
| Nancy Andrews | Member of the administrative board |
| Simon Moroney | Member of the administrative board |
| Ana de Pro Gonzalo | Member of the administrative board |
| Bridgette Heller | Member of the administrative board |
| Daniel Hochstrasser | Member of the administrative board |
| Frans van Houten | Member of the administrative board |
| John Young | Member of the administrative board |
| Mary Doherty | Member of the administrative board |
| Patrice Bula | Member of the administrative board |
| Ton Büchner | Member of the administrative board |
| William Winters | Member of the administrative board |
| Hans Jörg Reinhardt | Chairman of the administrative board |